Skip to content

Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract

Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03587558
Acronym
FOREVER
Enrollment
104
Registered
2018-07-16
Start date
2017-09-05
Completion date
2020-12-31
Last updated
2018-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carvedilol, Outflow Tract, Ventricular Premature Complexes

Keywords

carvedilol, SOICR, triggered activity, outflow tract PVC/VT

Brief summary

Carvedilol is known to be effective in reducing ventricular arrhythmias and mortality in patients with heart failure. It is suggested that one of the mechanisms is its ability to block store overload-induced Calcium release which activates spontaneous calcium release by Ryanodine receptors. Ventricular outflow tract tachyarrhythmia is known to be associated with calcium overload due to activation of Ryanodine receptors. The aim of this study is to evaluate the efficacy of Carvedilol on premature ventricular complex(PVC)/ventricular tachycardia(VT) originating from outflow tract.

Detailed description

Carvedilol is one of the third-generation beta-blockers effective in reducing ventricular arrhythmias and mortality in patients with heart failure. Antioxidative and alpha - blocking effects, along with nonselective beta - blockade, have been described as a mechanism of effect in various diseases. The antiarrhythmic effect of carvedilol inhibiting atrial fibrillation or ventricular arrhythmia has been reported, but its mechanism is not yet clear. Among them, inhibition of store overload-induced Ca2+ release (SOICR) is suggested as an antiarrhythmic mechanism of carvedilol. Stimulation of the beta receptor leads to the entry of calcium into the sarcoplasmic reticulum (SR) by opening the L-type calcium channel. The influx of calcium through the L-type calcium channel also increases the calcium release through the Ryanodine receptor (RyR) in the sarcoplasmic reticulum. This is called Ca-induced Ca release and is known as a normal physiological response. However, when calcium overload in the myofibrillar body occurs, spontaneous calcium release, known as SOICR, can occur through RyR, which can make triggered activity by inducing Na+/Ca2+ exchanger present in myocardium, leading to severe arrhythmia. Among several beta-blockers, only carvedilol has been known as a drug that can directly inhibit SOICR in combination with beta-blockade effect. Ventricular tachyarrhythmia originating from the ventricular outflow tract is an arrhythmia occurring in a patient with normal cardiac function. The mechanism of the arrhythmia is known to be triggered activity which is caused by activation of RyR due to increased cyclic adenosine monophasphate, resulting in calcium overload, eventually causing activation of Na+/Ca2+ exchanger. The aim of this study is to evaluate the efficacy of Carvedilol on PVC/VT originating from outflow tract.

Interventions

DRUGCarvedilol

Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT.

DRUGFlecainide

Patients in this group are taking flecainide to inhibit outflow tract PVC/VT.

Sponsors

Chong Kun Dang Pharmaceutical Corp.
CollaboratorINDUSTRY
Keimyung University Dongsan Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients with ventricular premature complexes/ventricular tachycardias originating from ventricular outflow tract confirmed on the 12-lead surface ECG * Patients with PVC burden of 5% or more in 24-hour Holter monitoring * Patients with normal left ventricular function * left ventricular ejection fraction ≥50% * Patients without structural heart disease

Exclusion criteria

* Pregnant, trying to become pregnant or breast feeding * History of bronchial asthma * History of coronary arterial disease

Design outcomes

Primary

MeasureTime frameDescription
PVC burden3 months after reaching the maximum tolerated dosePercentage of PVC/VT beat out of 24 hour total heart beat in Holter monitoring

Secondary

MeasureTime frameDescription
Symptom assessment scale3 months after reaching the maximum tolerated dosequestionnaire for PVC/VT symptoms using symptom assessment scale (Min 0 to Max 100)
Side effect of drugs3 months after reaching the maximum tolerated doseDifference in occurrence of side effects of each drug

Countries

South Korea

Contacts

Primary ContactJongmin Hwang, M.D., Ph.D.
dsmcep@dsmc.or.kr+82-53-250-7333

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026